The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: The optimal duration of antibiotic treatment for community-acquired pneumonia (CAP) has not been well established. OBJECTIVE: To validate Infectious Diseases Society of America/American Thoracic Society guidelines for duration of antibiotic treatment in hospitalized patients with CAP. DESIGN, SETTING, AND PARTICIPANTS: This study was a multicenter, noninferiority randomized clinical trial performed at 4 teaching hospitals in Spain from January 1, 2012, through August 31, 2013. A total of 312 hospitalized patients diagnosed as having CAP were studied. Data analysis was performed from January 1, 2014, through February 28, 2015. INTERVENTIONS: Patients were randomized at day 5 to an intervention or control group. Those in the intervention group were treated with antibiotics for a minimum of 5 days, and the antibiotic treatment was stopped at this point if their body temperature was 37.8°C or less for 48 hours and they had no more than 1 CAP-associated sign of clinical instability. Duration of antibiotic treatment in the control group was determined by physicians. MAIN OUTCOMES AND MEASURES: Clinical success rate at days 10 and 30 since admission and CAP-related symptoms at days 5 and 10 measured with the 18-item CAP symptom questionnaire score range, 0-90; higher scores indicate more severe symptoms. RESULTS: Of the 312 patients included, 150 and 162 were randomized to the control and intervention groups, respectively. The mean (SD) age of the patients was 66.2 (17.9) years and 64.7 (18.7) years in the control and intervention groups, respectively. There were 95 men (63.3%) and 55 women (36.7%) in the control group and 101 men (62.3%) and 61 women (37.7%) in the intervention group. In the intent-to-treat analysis, clinical success was 48.6% (71 of 150) in the control group and 56.3% (90 of 162) in the intervention group at day 10 (P = .18) and 88.6% (132 of 150) in the control group and 91.9% (147 of 162) in the intervention group at day 30 (P = .33). The mean (SD) CAP symptom questionnaire scores were 24.7 (11.4) vs 27.2 (12.5) at day 5 (P = .10) and 18.6 (9.0) vs 17.9 (7.6) at day 10 (P = .69). In the per-protocol analysis, clinical success was 50.4% (67 of 137) in the control group and 59.7% (86 of 146) in the intervention group at day 10 (P = .12) and 92.7% (126 of 137) in the control group and 94.4% (136 of 146) in the intervention group at day 30 (P = .54). The mean (SD) CAP symptom questionnaire scores were 24.3 (11.4) vs 26.6 (12.1) at day 5 (P = .16) and 18.1 (8.5) vs 17.6 (7.4) at day 10 (P = .81). CONCLUSIONS AND RELEVANCE: The Infectious Diseases Society of America/American Thoracic Society recommendations for duration of antibiotic treatment based on clinical stability criteria can be safely implemented in hospitalized patients with CAP. TRIAL REGISTRATION: clinicaltrialsregister.eu Identifier: 2011-001067-51.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Mandell, L. A., Wunderink, R. G., Anzueto, A., Bartlett, J. G., Campbell, G. D., Dean, N. C., Dowell, S. F., File, T. M., Musher, D. M., Niederman, M. S., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/511159 · Cited by 6,202
A Prediction Rule to Identify Low-Risk Patients with Community-Acquired Pneumonia
Fine, M. J., Auble, T. E., Yealy, D. M., Hanusa, B. H., Weissfeld, L. A., Singer, D. E., Coley, C. M., Marrie, T. J., & Kapoor, W. N. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701233360402 · Cited by 4,582
Katz, S. (1963) · JAMA · doi:10.1001/jama.1963.03060120024016 · Cited by 2,421
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
Lim, W. S., Baudouin, S. V., George, R. C., Hill, A. T., Jamieson, C., Le Jeune, I., Macfarlane, J. T., Read, R. C., Roberts, H. J., Levy, M. L., et al. (2009) · Thorax · doi:10.1136/thx.2009.121434 · Cited by 1,420
Chastre, J., Wolff, M., Fagon, J.-Y., Chevret, S., Thomas, F., Wermert, D., Clementi, E., Gonzalez, J., Jusserand, D., Asfar, P., et al. (2003) · JAMA · doi:10.1001/jama.290.19.2588 · Cited by 1,376
Clinical and economic burden of community-acquired pneumonia among adults in Europe
Welte, T., Torres, A., & Nathwani, D. (2012) · Thorax · doi:10.1136/thx.2009.129502 · Cited by 1,033
Guillemot, D., Carbon, C., Balkau, B., Geslin, P., Lecoeur, H., Vauzelle-Kervroëdan, F., Bouvenot, G., & Eschwége, E. (1998) · JAMA · doi:10.1001/jama.279.5.365 · Cited by 545
Halm, E. A., Fine, M. J., Marrie, T. J., Coley, C. M., Kapoor, W. N., Obrosky, D. S., & Singer, D. E. (1998) · JAMA · doi:10.1001/jama.279.18.1452 · Cited by 518
Guidelines for the management of adult lower respiratory tract infections - Summary
Woodhead, M., Blasi, F., Ewig, S., Garau, J., Huchon, G., Ieven, M., Ortqvist, A., Schaberg, T., Torres, A., van der Heijden, G., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03602.x · Cited by 468
Moussaoui, R. E., de Borgie, C. A. J. M., van den Broek, P., Hustinx, W. N., Bresser, P., van den Berk, G. E. L., Poley, J.-W., van den Berg, B., Krouwels, F. H., Bonten, M. J. M., et al. (2006) · BMJ · doi:10.1136/bmj.332.7554.1355 · Cited by 339
High‐Dose, Short‐Course Levofloxacin for Community‐Acquired Pneumonia: A New Treatment Paradigm
Dunbar, L. M., Wunderink, R. G., Habib, M. P., Smith, L. G., Tennenberg, A. M., Khashab, M. M., Wiesinger, B. A., Xiang, J. X., Zadeikis, N., & Kahn, J. B. (2003) · Clinical Infectious Diseases · doi:10.1086/377539 · Cited by 335
Development and Validation of a Clinical Prediction Rule for Severe Community-acquired Pneumonia
España, P. P., Capelastegui, A., Gorordo, I., Esteban, C., Oribe, M., Ortega, M., Bilbao, A., & Quintana, J. M. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-177oc · Cited by 327
Self-citationRisk factors of treatment failure in community acquired pneumonia: implications for disease outcome
Menendez, R. (2004) · Thorax · doi:10.1136/thx.2003.017756 · Cited by 319
Ramirez, J. A., Vargas, S., Ritter, G. W., Brier, M. E., Wright, A., Smith, S., Newman, D., Burke, J., Mushtaq, M., & Huang, A. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.20.2449 · Cited by 236
Schrag, S. J., Peña, C., Fernández, J., Sánchez, J., Gómez, V., Pérez, E., Feris, J. M., & Besser, R. E. (2001) · JAMA · doi:10.1001/jama.286.1.49 · Cited by 233
Patient compliance with antibiotic treatment for respiratory tract infections
Kardas, P. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf046 · Cited by 223
Oosterheert, J. J., Bonten, M. J. M., Schneider, M. M. E., Buskens, E., Lammers, J.-W. J., Hustinx, W. M. N., Kramer, M. H. H., Prins, J. M., Slee, P. H. T. J., Kaasjager, K., et al. (2006) · BMJ · doi:10.1136/bmj.38993.560984.be · Cited by 194
The Community-Acquired Pneumonia Symptom Questionnaire
Lamping, D. L., Schroter, S., Marquis, P., Marrel, A., Duprat-Lomon, I., & Sagnier, P.-P. (2002) · Chest · doi:10.1378/chest.122.3.920 · Cited by 162
Menéndez, R., Torres, A., Aspa, J., Capelastegui, A., Prat, C., & Rodríguez de Castro, F. (2010) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2010.06.014 · Cited by 162
Self-citationShort- versus Long-Course Antibacterial Therapy for Community-Acquired Pneumonia: A Meta-Analysis
Dimopoulos, G., Matthaiou, D. K., Karageorgopoulos, D. E., Grammatikos, A. P., Athanassa, Z., & Falagas, M. E. (2008) · Drugs · doi:10.2165/00003495-200868130-00004 · Cited by 160
Jastaniah, A., & Hameed, M. S. (2019) · CRC Press eBooks · doi:10.1201/9780429316944-86 · Cited by 134
Efficacy of Short-Course Antibiotic Regimens for Community-Acquired Pneumonia: A Meta-analysis
Maurer, J. (2009) · Yearbook of Pulmonary Disease · doi:10.1016/s8756-3452(08)79054-6 · Cited by 123
O’Doherty, B., & Muller, O. (1998) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960050201 · Cited by 106
Epidemiology and etiology of community-acquired pneumonia
Mandell, L. A. (2004) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2004.08.003 · Cited by 92
Stability in community-acquired pneumonia: one step forward with markers?
Menéndez, R., Martinez, R., Reyes, S., Mensa, J., Polverino, E., Filella, X., Esquinas, C., Martinez, A., Ramírez, P., & Torres, A. (2009) · Thorax · doi:10.1136/thx.2009.118612 · Cited by 90
Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia
Torres, A., Muir, J.-F., Corris, P. A., Kubin, R., Duprat-Lomon, I., Sagnier, P., & Höffken, G. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00045202 · Cited by 86
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Aliberti, S., Blasi, F., Zanaboni, A. M., Peyrani, P., Tarsia, P., Gaito, S., & Ramírez, J. A. (2009) · European Respiratory Journal · doi:10.1183/09031936.00130909 · Cited by 77
D'Ignazio, J., Camere, M. A., Lewis, D. E., Jorgensen, D. M., & Breen, J. D. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.10.4035-4041.2005 · Cited by 69
File, T. M., Mandell, L. A., Tillotson, G. S., Kostov, K., & Georgiev, O. B. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm119 · Cited by 68
Clinical Efficacy of Newer Agents in Short-Duration Therapy for Community-Acquired Pneumonia
File, T. M. (2004) · Clinical Infectious Diseases · doi:10.1086/421354 · Cited by 64
Choudhury, G., Mandal, P., Singanayagam, A., Akram, A. R., Chalmers, J. D., & Hill, A. T. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03542.x · Cited by 59
Siegel, R. E., Alicea, M., Lee, A. M., & Blaiklock, R. G. (1999) · American Journal of Therapeutics · doi:10.1097/00045391-199907000-00007 · Cited by 55
Bordón, J., Aliberti, S., Duvvuri, P. D., Wiemken, T. L., Peyrani, P., Natividad, I., Caceres-Lara, A., Delapenha, R., Blasi, F., & Ramírez, J. A. (2013) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2012.09.021 · Cited by 32
Léophonte, P., Choutet, P., GAILLAT, J., PETITPRETZ, P., Portier, H., Montestruc, F., Pecking, M., & BELS, F. D. (2002) · Médecine et Maladies Infectieuses · doi:10.1016/s0399-077x(02)00384-0 · Cited by 29
Sopena, N., Martínez-Vázquez, C., Rodríguez-Suárez, J., Segura, F., Valencia, Á. G., & Sabrià, M. (2004) · Journal of Chemotherapy · doi:10.1179/joc.2004.16.1.102 · Cited by 23
How to choose the duration of antibiotic therapy in patients with pneumonia
Aliberti, S., Giuliani, F., Ramírez, J. A., & Blasi, F. (2015) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000140 · Cited by 20
&NA; (2002) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200202000-00027 · Cited by 20
Menéndez, R., Torres, A., Aspa, J., Capelastegui, A., & Prat, C. (2010) · Cited by 13
Self-citation
Cited by
Metlay, J. P., Waterer, G. W., Long, A. C., Anzueto, A., Brozek, J., Crothers, K., Cooley, L. A., Dean, N. C., Fine, M. J., Flanders, S. A., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1581st · Cited by 3,657
Aliberti, S., Dela Cruz, C. S., Amati, F., Sotgiu, G., & Restrepo, M. I. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00630-9 · Cited by 305
The new antibiotic mantra-“shorter is better”.
Spellberg, B. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.3646 · Cited by 291
Oral amoxicillin and amoxicillin–clavulanic acid: properties, indications and usage
Huttner, A., Bielicki, J., Clements, M. N., Frimodt-Møller, N., Muller, A. E., Paccaud, J.-P., & Mouton, J. W. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.11.028 · Cited by 270
The antibiotic course has had its day
Llewelyn, M. J., Fitzpatrick, J. M., Darwin, E., SarahTonkin-Crine, Gorton, C., Paul, J., Peto, T. E. A., Yardley, L., Hopkins, S., & Walker, A. S. (2017) · BMJ · doi:10.1136/bmj.j3418 · Cited by 269
Metadata
- Authors
- Uranga, A., España, P. P., Bilbao, A., Quintana, J. M., Arriaga, I., Intxausti, M., Lobo, J. L., Tomás, L., Camino, J., Nuñez, J., & Capelastegui, A.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2016-09-01
- Volume
- 176
- Issue
- 9
- Pages
- 1257
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W2475845335
- Cited by
- 290
- References
- 39
- FWCI
- 26.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.